WECARE APD: Assessing a Single Multidisciplinary Team Visit for Atypical Parkinsonian Disorders
WECARE APD
WECARE APD: Randomized Trial to Evaluate the Impact of a Single Multidisciplinary Team Visit for Atypical Parkinsonian Disorders: a Feasibility Study
1 other identifier
interventional
30
0 countries
N/A
Brief Summary
Atypical Parkinsonian disorders (APD) are a group of brain disorders that look like Parkinson's disease but progress faster and don't respond well to common treatments like levodopa. These conditions include Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and Multiple System Atrophy (MSA). Caring for APD patients is especially challenging because the symptoms worsen quickly and require multiple specialists, often leading to separate visits with different doctors and therapists. This not only increases the burden on patients and caregivers but also results in high medical costs. Despite the serious impact of APD, there is no proven care model that significantly improves the quality of life for patients and their caregivers. To address this, the investigator team has created a novel type of clinic that brings together a team of specialists in a shared appointment to provide comprehensive care in one visit. This study aims to test whether an early visit with this team, in addition to regular medical care, can improve quality of life, help patients manage their symptoms better, and reduce the stress on caregivers. The investigators will conduct a six-month study with two groups: one will receive the multidisciplinary care visit right away, while the other will continue with regular care and receive the visit after six months. Patients and caregivers will fill out questionnaires about their well-being at the beginning, after one month, and after six months. The study will also measure how practical it is to run this type of clinic, making sure enough people participate, complete the required surveys, and stay in the study. This will be the first study to test whether a team-based care model is practical and beneficial for APD patients and their caregivers. If successful, it could serve as a foundation for larger studies and potentially improve care for other complex neurological conditions in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2025
CompletedFirst Posted
Study publicly available on registry
February 20, 2025
CompletedStudy Start
First participant enrolled
March 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2026
ExpectedFebruary 20, 2025
January 1, 2025
10 months
January 29, 2025
February 15, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Percentage of Eligible Participants Willing to be Randomized
Definition: The proportion of eligible participants who consent to randomization in the study. Measurement: Total number of eligible participants approached for the study. Number of participants who provide informed consent and agree to be randomized. Formula: Percentage Willing=( Total Eligible Participants Approached Participants Consented and Randomized )×100
From screening to enrollment , 12 months after study start
Percentage of Participants Completing Outcome Assessment
Definition: The proportion of participants who successfully complete all required outcome assessments at designated time points. Measurement: Tracking the number of participants who complete each outcome assessment. Comparison of completion rates across different study arms. Formula: Completion Rate=(Participants Who Complete All Required Assessments Total Participants Enrolled)×100
At 6 months after randomization
Satisfaction survey (Quantitative)
Response Categories (5-point Likert scale): Very satisfied Satisfied Neutral Unsatisfied Very unsatisfied Analysis Approach: Responses will be dichotomized into: Satisfied: Very satisfied + Satisfied Not Satisfied: Neutral + Unsatisfied + Very unsatisfied The proportion of participants in each category will be calculated. Formula: Satisfaction Rate =(Satisfied Responses Total Responses)×100
After 6 months of randomization
Study Arms (2)
Multidisciplinary clinic visit arm
EXPERIMENTALThe multidisciplinary clinic visit will follow a shared appointment model and involve a specialized team consisting of a movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist, an occupational therapist, a speech-language pathologist, and a social worker. Care will be provided in an outpatient setting at a University Hospital. Before the initial visit, patients with APS and their care partners will complete a pre-visit questionnaire to identify their top three care priorities. During the visit, the multidisciplinary team will meet with the patient and their care partner in a single appointment room, beginning the session by addressing the identified priority issues. The team will collaboratively discuss management strategies, emphasizing self-management, and provide real-time guidance and recommendations. If needed, hands-on physiotherapy and occupational therapy evaluations will be conducted during the
Waitlist arm
OTHERParticipants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.
Interventions
Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.
The multidisciplinary clinic visit will use a shared appointment model and will include a specialized team comprising movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist (PT), an occupational therapist (OT), a speech-language pathologist, and a social worker. Care will be delivered in an outpatient setting at a University Hospital. Prior to the initial visit, patients with APS and their care partners will receive a pre-visit questionnaire to identify their top three care priorities. During the visit, the multidisciplinary team will convene with the patient and their care partner in a single appointment room. The session will begin by addressing each of the priority issues identified by the patient and care partner. The team will collaboratively discuss management strategies, focusing on self-management, and will provide real-time guidance and recommendations. As indicated, hands-on PT and OT evaluatio
Eligibility Criteria
You may qualify if:
- Participants must be older than 40 years.
- The participant must meet the standard international consensus criteria for a clinically probable diagnosis of one of the following neurodegenerative conditions:Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP);Cortico-Basal Syndrome (CBS)
You may not qualify if:
- Severe Physical or Cognitive Limitations:
- Participants must be able to attend the clinic.
- Individuals with severe physical disabilities or cognitive impairments that prevent clinic attendance will be excluded.
- Life-Threatening Comorbidities:
- Participants with severe, advanced medical conditions that significantly impact survival or functional ability will be excluded. These include, but are not limited to:End-stage renal disease (ESRD) requiring dialysis; End-stage congestive heart failure (CHF) with severe functional impairment; Advanced malignancy (such as metastatic cancer or terminal cancer with limited prognosis).
- Living in long-term care, away from the care-partner
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
January 29, 2025
First Posted
February 20, 2025
Study Start
March 15, 2025
Primary Completion
December 31, 2025
Study Completion (Estimated)
July 20, 2026
Last Updated
February 20, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share